Suppr超能文献

缓激肽B2受体拮抗剂Hoe 140在不同物种离体血管中的激动和拮抗特性

Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, Hoe 140, in isolated blood vessels from different species.

作者信息

Félétou M, Germain M, Thurieau C, Fauchère J L, Canet E

机构信息

Institut de Recherches Servier, Suresnes, France.

出版信息

Br J Pharmacol. 1994 Jun;112(2):683-9. doi: 10.1111/j.1476-5381.1994.tb13130.x.

Abstract
  1. Hoe 140, a recently described bradykinin B2 antagonist, and NPC 567 from an earlier generation of bradykinin B2 antagonists, were tested in rabbit and sheep isolated blood vessels. 2. In rabbit jugular vein, a bradykinin B2 preparation, NPC 567 was an antagonist (apparent pA2: 8.67 +/- 0.16) with marked residual agonistic activity (log[EC50]: -7.29 +/- 0.13). Hoe 140 was a potent non-competitive antagonist devoid of agonistic properties (slope of the Schild plot: 2.02; estimated pA2: 9.04). 3. In rabbit aorta, a bradykinin B1 preparation, NPC 567 was a competitive antagonist (pA2: 6.32 +/- 0.13) but Hoe 140 was ineffective. The two antagonists did not show any agonistic properties in this tissue. 4. In sheep femoral artery without endothelium, bradykinin and Hoe 140 induced contractions with identical efficacy and similar potency (log[EC50]: -8.05 +/- 0.12, -7.73 +/- 0.10; maximal contraction in % of KCl [60 mM]: 59.5 +/- 15.1, 62.0 +/- 13.1; for bradykinin and Hoe 140, respectively). In contrast NPC 567 was an extremely weak agonist. The contractile responses to bradykinin and Hoe 140 were inhibited by NPC 567 (apparent pKB: 6.89 +/- 0.22 and 6.58 +/- 0.08 versus bradykinin and Hoe 140, respectively) but not by a B1 bradykinin antagonist, suggesting that the receptor involved was a bradykinin B2 receptor. 5. In sheep femoral artery with endothelium, bradykinin induced a biphasic response: an endothelium-dependent relaxation and a contraction which were both inhibited by NPC 567 (apparent pKB: 7.10 +/- 0.15) and Hoe 140 (pA2: 8.38 +/- 0.12). As bradykinin B2 receptor antagonists, Hoe 140 and NPC 567 were less potent in the sheep femoral artery than in the rabbit jugular vein. Neither Hoe 140 nor NPC 567 were agonists for the endothelial receptor.6. This study demonstrates that Hoe 140, a new bradykinin B2 receptor antagonist, is more selective and more potent than NPC 567; however, it may possess, depending on the tissue studied, marked residual agonistic properties. Furthermore, bradykinin B2 receptors are subject to important species specificity. Finally, two different bradykinin B2 receptor subtypes may coexist in the sheep femoral artery with endothelium.
摘要
  1. Hoe 140是一种最近被描述的缓激肽B2拮抗剂,NPC 567来自早期一代的缓激肽B2拮抗剂,它们在兔和羊的离体血管中进行了测试。2. 在兔颈静脉(一种缓激肽B2制剂)中,NPC 567是一种拮抗剂(表观pA2:8.67±0.16),具有明显的残余激动活性(log[EC50]:-7.29±0.13)。Hoe 140是一种强效的非竞争性拮抗剂,无激动特性(Schild图的斜率:2.02;估计pA2:9.04)。3. 在兔主动脉(一种缓激肽B1制剂)中,NPC 567是一种竞争性拮抗剂(pA2:6.32±0.13),但Hoe 140无效。这两种拮抗剂在该组织中均未表现出任何激动特性。4. 在无内皮的羊股动脉中,缓激肽和Hoe 140诱导的收缩具有相同的效力和相似的效价(log[EC50]:-8.05±0.12,-7.73±0.10;相对于60 mM KCl的最大收缩率[%]:59.5±15.1,62.0±13.1;分别针对缓激肽和Hoe 140)。相比之下,NPC 567是一种极其微弱的激动剂。NPC 567抑制了对缓激肽和Hoe 140的收缩反应(相对于缓激肽和Hoe 140,表观pKB分别为6.89±0.22和6.58±0.08),但未被B1缓激肽拮抗剂抑制,这表明所涉及的受体是缓激肽B2受体。5. 在有内皮的羊股动脉中,缓激肽诱导双相反应:内皮依赖性舒张和收缩,两者均被NPC 567(表观pKB:7.10±0.15)和Hoe 140(pA2:8.38±0.12)抑制。作为缓激肽B2受体拮抗剂,Hoe 140和NPC 567在羊股动脉中的效力低于兔颈静脉。Hoe 140和NPC 567均不是内皮受体的激动剂。6. 本研究表明,新型缓激肽B2受体拮抗剂Hoe 140比NPC 567更具选择性和效力;然而,根据所研究的组织不同,它可能具有明显的残余激动特性。此外,缓激肽B2受体具有重要的物种特异性。最后,两种不同的缓激肽B2受体亚型可能共存于有内皮的羊股动脉中。

相似文献

2
In vitro effects of HOE 140 in human bronchial and vascular tissue.
Eur J Pharmacol. 1995 Feb 14;274(1-3):57-64. doi: 10.1016/0014-2999(94)00709-g.
5
Bradykinin receptor types and B2 subtypes.
Life Sci. 1994;55(10):735-49. doi: 10.1016/0024-3205(94)00557-5.
10
DesArg10[Hoe 140] is a potent B1 bradykinin antagonist.
Agents Actions Suppl. 1992;38 ( Pt 2):406-13.

引用本文的文献

4
Analgesic targets: today and tomorrow.镇痛靶点:现在与未来。
Inflammopharmacology. 2009 Jun;17(3):151-61. doi: 10.1007/s10787-009-0006-z. Epub 2009 Jun 9.

本文引用的文献

6
Histamine release from rat peritoneal mast cells by kinin antagonists.
Eur J Pharmacol. 1988 Apr 27;149(1-2):137-40. doi: 10.1016/0014-2999(88)90051-9.
9
New, long-acting, potent bradykinin antagonists.新型长效强效缓激肽拮抗剂。
Br J Pharmacol. 1991 Feb;102(2):297-304. doi: 10.1111/j.1476-5381.1991.tb12169.x.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验